Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoided by removing T lymphocytes from the donor bone marrow. However, T cell depletion increases the risk of graft rejection. In this study, two strategies are used to overcome rejection: (1) use of high doses of stem cells obtained from peripheral blood (PBSC), (2) admixture with a CD52 monoclonal antibody in order to deplete both donor and residual recipient lymphocytes. Two antibodies are compared: CAMPATH-1G (rat IgG2b) and its humanized equivalent CAMPATH-1H (human IgG1). A total of 187 consecutive patients at six centers received PBSC transplants from HLA-matched siblings between 1997 and 1999. A wide spectrum of diseases, both malignant and non-malignant, was included. The recovery of CD34 + cells after antibody treatment was close to 100%. The risk of acute GVHD (grade 2 to 4) was 11% in the CAMPATH-1G group and 4% in the CAMPATH-1H group (P = NS). The risk of chronic GVHD (any grade) was 11% in the CAMPATH-1G group and 24% in the CAMPATH-1H group (P = 0.03) but the risk of extensive chronic GVHD was only 2%. The overall risk of graft failure/rejection was 2%, not significantly different between the two antibodies. Antibody treatment was equally effective at concentrations between 10 g/ml and 120 g/ml and it made no significant difference to the outcome whether the patients received post-transplant immunosuppression or not (87% did not). Transplant-related mortality in this heterogenous group of patients (including high-risk and advanced disease) was 22% at 12 months. It is proposed that treatment of peripheral blood stem cells with CAMPATH-1H is a simple and effective method for depleting T cells which may be applicable to both autologous and allogeneic 
Transplantation of allogeneic stem cells is a curative therapy for patients with congenital or acquired deficits of hemopoeisis. Combined with high-dose chemotherapy and radiotherapy, it is also a very effective treatment for hematologic malignancies. In recent years, it has become possible to harvest large numbers of stem cells from peripheral blood following mobilization with growth factors, and this is likely to eliminate the need for aspiration of donor bone marrow. However, all forms of allogeneic stem cell transplantation suffer from adverse effects, the most serious being graft-versus-host disease (GVHD), caused by attack of the donor T cells on recipient tissue. Despite the best immunosuppressive therapy with combinations of cyclosporin and methotrexate, this remains a significant cause of morbidity and mortality. If it were not for side-effects such as GVHD, allogeneic stem cell transplantation might be considered for treatment of other conditions, such as autoimmune diseases and induction of tolerance to organ transplants.
GVHD can be prevented by depleting T lymphocytes from the donor stem cells and there are several methods to accomplish this. In 1983 we developed the monoclonal antibody CAMPATH-1M, a rat IgM antibody which recognizes the CD52 antigen.
1 CD52 is abundantly expressed on all human lymphocytes and is an exceptionally good target for cell lysis by antibody with human complement. This provided a simple method for purging the donor T cells 2 which was very effective and gave a significant reduction in GVHD. 3, 4 However, the benefit was offset by an
Bone Marrow Transplantation increased risk of graft rejection by residual host T cells. 5, 6 Animal models showed that this might be overcome by using monoclonal antibodies to deplete residual host T cells. 7 A rat IgG2b CD52 antibody, CAMPATH-1G, effectively depletes human lymphocytes in vivo. 8 Like CAM-PATH-1M, it can activate human complement, although this is not sufficient for systemic T cell depletion. Rat IgG2b also binds human Fc receptors and engages cellular killing mechanisms (ADCC). 9 The combination of CAM-PATH-1M to T cell deplete donor bone marrow and the intravenous injection of CAMPATH-1G to ablate residual host immunity overcomes both the problems of GVHD and graft rejection and results in a significantly decreased transplant-related mortality compared with conventional long-term immunosuppressive therapy. 10 However, a simpler strategy was to use a single dose of CAMPATH-1G added to donor bone marrow to accomplish both objectives at once. Some antibody binds to donor T cells opsonizing them for subsequent clearance. The excess antibody is infused along with the bone marrow and gives sufficient depletion of residual host T cells to prevent rejection. 3, 4, 11 We therefore wondered if the same simple method could be used with peripheral blood stem cells. In this case, the number of contaminating T cells is potentially larger and may be quite variable, according to the exact mobilization and collection protocols.
In 1988, a humanized version of CAMPATH-1G was described, 12 namely CAMPATH-1H. This antibody is being developed for the treatment of CLL. 13, 14 CAMPATH-1H is a human IgG1, chosen for its optimal effector function and in principle it should be equally as effective as CAMPATH-1G for elimination of T cells in vivo. There is already a lot of data to support this concept from clinical trials with CAMPATH-1H in CLL, rheumatoid arthritis, multiple sclerosis and organ transplantation. 1 Here, CAMPATH-1G and CAMPATH-1H are compared for use in allogeneic stem cell transplantation and by consideration of the heterogeneity of actual stem cell donations, the robustness of the treatment protocol is assessed.
Patients and methods

Monoclonal antibodies
CAMPATH-1G
15 was prepared from the culture supernatant of hybrid myeloma cells cultured in a hollow fibre fermentor (Acusyst-Jr, Cellex Biosciences, Merseyside, UK). It was purified by affinity chromatography on Protein A Sepharose, followed by ion exchange chromatography on S-Sepharose and formulated in phosphate-buffered saline. CAMPATH-1H 12, 16 was prepared from the culture supernatant of Chinese hamster ovary (CHO) cell transfectants in the same way, but also subjected to a final purification by size exclusion chromatography on Superdex 200. The antibodies were tested in a variety of analytical systems for purity, potency and freedom from contaminants before release to the clinic.
Collection of peripheral blood stem cells
Donors were treated with G-CSF s.c. at between 5 and 20 g/kg/24 h in order to achieve a white cell count between 20 and 50 × 10 9 per litre by day 5. Apheresis was started approx 2 h after the last dose of G-CSF and continued for up to 6 h. The anticoagulant was ACD-A, typically one volume for every 10-12 volumes of blood. Based on the ideal body weight of the patient, the target cell dose was either 5 × 10 8 mononuclear cells/kg or 4-5 × 10 6 CD34 + cells/kg. This typically required the processing of 10 to 20 litres of blood. In the event that the target cell dose was not achieved, the apheresis procedure was repeated the following day subject always to the safety and tolerability of the procedure for the donor. No donors were subjected to more than two aphereses. Special procedures were established for donors Ͻ35 kg according to local requirements. The volume of each apheresis unit was measured and the concentration of mononuclear cells determined using a suitable automated differential cell counter.
Treatment with monoclonal antibody
CAMPATH-1G or CAMPATH-1H was added to the stem cell concentrate, gently mixed and kept for 30 min at room temperature (18-25°C). The target dose of antibody was either 10 mg or 20 mg according to local protocol, but additional antibody was sometimes added up to a maximum of 60 mg when the volume or number of cells was particularly high. In the event that two apheresis units were collected, standard procedure was to apportion the antibody dose between them. The entire cell suspension was then infused to the recipient over 30 to 60 min without further manipulation according to standard local procedures. Various premedications were used to ameliorate the expected flu-like symptoms due to cytokine release caused by the antibody, including paracetamol (acetaminophen) with either 100 mg hydrocortisone plus 12.5 mg phenergan (promethazine hydrochloride), or prednisone (2 mg/kg) given 1 h before the graft. 17 
Measurement of cell subpopulations
Mononuclear cells were measured with electronic cell counters and calculated as the combination of lymphocytes plus monocytes from differential cell counts. CD34
+ progenitors and CD3
+ T cells were enumerated by flow cytometry both before and after the antibody treatment. CD34 + cells were measured according to the guidelines of the International Society for Hematotherapy and Graft Engineering 18 using phycoerythrin-labelled CD34 antibody and FITC-labelled CD45 antibody.
Patients
Six transplant centers participated in the study: A-Z St Jan, Bruges; Groote Schuur Hospital, Cape Town; Constantiaberg Medi-Clinic, Cape Town; Hopital Cantonal, Geneva; University Hospital, Leiden; Ulm University Hospital, Ulm. They are arbitrarily coded 1-6. Each center recruited consecutive patients provided that they gave informed con-sent. Data were collected on all patients who received stem cell transplants treated in vitro with CAMPATH-1G or CAMPATH-1H up till May 1999 (a total of 217 patients). For this analysis, 30 patients were excluded who received transplants from donors other than HLA-matched siblings or who also received CAMPATH-1 antibodies in vivo as part of the conditioning regimen. All categories of disease, conditioning regimens and post-transplant immunosuppression were included, representing the range of normal practice at each center.
Statistical analysis
Characteristics of the treatment groups and outcomes were compared using the chi-square test for categorical variables and the Mann-Whitney-Wilcoxon rank sum test for continuous variables. Time-dependent outcomes (engraftment, survival) were compared by the log-rank test. Multifactorial non-linear regression was used to analyze the possible relationship between GVHD and the following covariates: patient sex, patient age, donor sex, type of antibody, posttransplant immunosuppression, antibody dose, antibody concentration, cell dose. These tests were carried out using the 'FIRST' suite of statistical software (Serious Statistical Software, Lynwood, South Wirral, UK) or 'LOGRANK' software (SP Cobbold, University of Oxford, Oxford, UK) running under the RISC operating system on an Acorn Archimedes computer.
Results
Study centers, conditioning regimens and patient characteristics
The purpose of this study was to test whether a single simple procedure for treatment of donor stem cells could be used with all types of patients. Therefore, consecutive patients were enrolled at each center with no selection according to type or stage of disease, and all other aspects of the transplant procedure (conditioning regimen, prophylactic antibiotics etc) continued according to the usual local procedures adapted as clinically required according to the status of the patient. Most patients received standard conditioning with cyclophosphamide plus total body irradiation (TBI), but where TBI was not indicated, a combination of chemotherapeutic agents was used (Table 1) . Two centers gave supplementary total lymphoid irradiation as anti-rejection prophylaxis. One center used only CAMPATH-1G for treatment of the stem cells, two used only CAMPATH-1H and three switched from the rat to the humanized antibody during the course of the study. Post-transplant immunosuppression with cyclosporin A (CyA) or a combination of CyA and methotrexate (MTX) was used routinely at only two centers. Three patients received donor leukocyte infusions post transplant for prevention or treatment of relapse. Other characteristics of the patient population are summarized in Table 2 .
Bone Marrow Transplantation Table 1 Conditioning regimens used at the six study centres Total lymphoid irradiation was given routinely by two centers in addition to TBI. This was increased to 1500 rad for three patients with aplastic anaemia who did not receive TBI. 
Recovery of cells from apheresis
The yields anticipated a priori for an adult apheresis unit were: volume 200 to 500 ml, total number of mononuclear cells 100 to 300 × 10 8 , CD34 + cells 100 to 300 × 10 6 . The median actual yields were approximately double the original targets but there were no major differences between the two groups of patients (Table 3) . There was a range of Probabilities (P) were calculated by the Mann-Whitney-Wilcoxon rank sum test. Differences in the numbers of CD34 + cells remained significant even after excluding data from one center which reported lower CD34
+ counts than others.
yields as a result of operational requirements. However, only 1% of donations fell below the lower limit of 100 × 10 8 mononuclear cells and 11% were below the limit of 100 × 10 6 CD34 + cells. All centers had a similar yield of mononuclear cells but Center 2 reported seven patients (58% of those tested) with less than 100 × 10 6 CD34 + cells. This center obtained a consistently lower percentage of CD34 + cells (median 0.11% pre-treatment), which might be due to differences in the mobilization protocol (typically a lower dose of G-CSF was used). As a result of these operational differences, there were some modest, but statistically significant differences in the cell yields between the two groups of patients (Table 3) , the CAMPATH-1H group having on average fewer CD34 + cells but more CD3 + cells.
Antibody treatment
Some centers adjusted the total dose of antibody in proportion to the volume of cell suspension to achieve a consistent final concentration; some used a fixed dose per apheresis unit and others used a fixed dose per patient. The outcome was that a range of antibody concentrations was achieved in practice. The median total dose of antibody was 10 mg (range 10-60 mg) for the CAMPATH-1G group and 20 mg (range 10-60 mg) for the CAMPATH-1H group (P Ͻ 0.0001). This resulted in a small, but significant increase in the final concentration of CAMPATH-1H (median 57 g/ml) compared with CAMPATH-1G (median 40 g/ml). The overall median was 56 g/ml (90% CI 10-120 g/ml). One objective of this analysis was to test whether the outcome depends on dose or concentration of antibody within this range. In every case the incubation conditions followed the protocol, ie 30 min at room temperature. The temperature was recorded as 20 to 25°C (median 20°C).
Cell recovery following antibody treatment
There were small differences between the two groups, but in both cases the recovery of CD34 + cells was very good (Table 3 ). The median recovery of mononuclear cells was 70% (90% CI 44-99%) and the total number infused was 6.7 × 10 8 per kg (90% CI 3.5-14 × 10 8 per kg), which was a little higher than the target of 5 × 10 8 per kg. The median recovery of CD34 + cells was 99% (90% CI 35-366%) and the total number infused was 6.3 × 10 6 per kg (90% CI 1-19 × 10 6 per kg), ie close to 1% of the mononuclear cells the median recovery of CD3 + cells was 26% (90% CI 5-65%). It was not expected that all the T cells would be lysed in vitro.
Engraftment and graft failure
Univariate analyses of outcome are shown in Table 4 . Recovery of neutrophils was rapid, as expected for peripheral blood stem cell transplants. The median day to reach 500 neutrophils/l was day 13 (range 10-44) for the CAM-PATH-1G group and day 12 (range 8-30) for the CAM-PATH-1H group. There was one case of early graft failure (never reached 500 neutrophils/l) and one case of late graft failure in each group.
Graft-versus-host disease
The incidence of both acute and chronic GVHD was higher in the CAMPATH-1H group compared with the CAM-PATH-1G group, almost entirely as a result of a higher frequency of grade 1 acute GVHD or mild/moderate chronic GVHD (Table 4) . However, neither the antibody dose nor the final antibody concentration had a significant effect on the incidence of GVHD. This is exemplified in The outcome is reported, together with the 95% confidence interval. Probabilities were calculated by the chi-squared test (GVHD) or the univariate log-rank test (other outcomes). They do not take into account any potential covariates. Figure 1 , where the mean GVHD grade is plotted against antibody concentration. Similar results (not shown) were obtained when mean grades for acute or chronic GVHD were plotted against total antibody dose or total cell dose. Furthermore, the use of post-transplant immunosuppression had no significant impact on the frequency of GVHD. The influences of potential covariates was examined by multi- A single underlying cause of death was assigned to each patient. Because of the small numbers, the differences in follow-up times (see Table 2 ) and the difficulty in assigning a unique cause to each case, statistical analysis is deemed to be impracticable.
variate linear regression with acute GVHD as the dependent variable and the following independent variables: patient sex, patient age, donor sex, type of antibody, post-transplant immunosuppression, antibody dose, antibody concentration, cell dose. The only factor found to be correlated with acute GVHD was the patients age -not surprisingly, there was an increasing risk of GVHD in older patients.
Mortality
Transplant-related mortality is defined as death from any cause other than relapse of the original disease. There was no significant difference between the groups (Table 4) . Because of the relatively short follow-up and the disparate diseases treated, there was no attempt to analyze relapse, overall survival or leukemia-free survival. The causes of death are listed in Table 5 . There was one death from EBVassociated lymphoproliferative disease. There were more deaths from infection in the CAMPATH-1H group (13%) than the CAMPATH-1G group (6%), although the difference is not statistically significant due to the relatively small numbers. As expected, there were relatively fewer deaths among the patients transplanted for early leukemia, but with the small numbers and short follow-up of this study, the differences were not statistically significant.
Comparison with reference groups of patients
No large reports are available from the transplant registries or other sources with which to compare these data. We selected three comparison groups of transplants from HLAmatched siblings in order to put the results into a clinical context. (1) Bone marrow transplants treated with CAM-PATH-1G ex vivo according to the present protocol. The patients are described in Refs 3, 4, 11 but the most recently updated data (previously unpublished) have been used. (2) PBSC transplants where GVHD prophylaxis consisted of either cyclosporin or tacrolimus combined with either methotrexate or prednisolone. Data from eight separate single-center studies were combined as described by Bensinger and Buckner. 19 The follow-up was short and so there are uncertainties in the calculation of chronic GVHD and transplant-related mortality. (3) PBSC transplants which had been T cell-depleted by positive selection of CD34 + cells by either an immunoadsorption or an immunomagnetic technique. 20 The comparative data are presented in Table 6 .
Discussion
Treatment of bone marrow with CAMPATH-1G has been established for some years as an effective method for depletion of donor T cells to prevent GVHD, without incurring a high risk of graft rejection. 3, 4, 11 In principle, engraftment is expected to be faster and more reliable from peripheral blood stem cells. However, it was not obvious whether the larger numbers of contaminating T cells could be dealt with as effectively by the antibody treatment. Furthermore, we wanted to test whether CAMPATH-1G could be replaced by the humanized version, CAMPATH-1H. This retrospective analysis of PBSC transplants at the participating centers was carried out to compare the outcomes according to the type of antibody used. Although certain aspects of the antibody treatment protocol were standardized in advance (eg time and temperature of treatment), other potentially important parameters were not so tightly controlled because of the varying logistical requirements of different patients. This provided an opportunity to determine the importance of factors such as antibody dose, concentration and post-transplant immunosuppression; in effect, a natural experiment to test the robustness of the procedure. Table 6 Comparison with other series of transplants 3,4,11 (2) PBSC transplants with drug-based GVHD prophylaxis. 19 Data marked * are incomplete due to short follow-up or limited reporting. Antibody concentration in the apheresis bag varied from 6 to 240 g/ml (median 56 g/ml, 90% CI 10-120 g/ml). The concentration of CAMPATH-1G or CAMPATH-1H required for 90% saturation of the CD52 antigen is approximately 10-20 g/ml.
12,21 However, maximal cell-mediated killing (ADCC) can be achieved with as little as 0.1 g/ml.
12 Therefore, in theory, even the lowest concentrations of antibody should have been adequate to opsonize the donor T cells for lysis in vivo.
Recoveries of mononuclear cells and CD34 + cells were consistently good with this procedure, which is not surprising, considering the simplicity of the manipulations. It is well documented that CAMPATH-1 antibodies spare hemopoietic colony-forming cells. 2, 22 However, there is a subpopulation of CD34 + cells in bone marrow which is also CD52 + and CD38 + , most probably lymphoid progenitors. 23 Treatment of bone marrow with CAMPATH-1G or CAM-PATH-1H can result in depletion of this subpopulation, but in peripheral blood CD34 + cells a similar CD52 + CD38
+ subpopulation was not detected. 24 In an experimental study, the concentrations of cells and antibody were systematically varied over a range corresponding to that achieved in clinical practice, but without effect on the depletion of lymphocytes or recovery of CD34 + cells. 24 It was not expected that treatment with CAMPATH-1G or CAMPATH-1H would result in extensive depletion of T cells prior to infusion into the patient. Although both antibodies can activate human complement, the conditions were not optimized for complement-mediated lysis. Some degree of depletion did occur in vitro, but the extent was highly variable (13-99%), probably because the amount of residual plasma was not specifically controlled. We believe that the main depleting effect occurs in vivo by antibodydependent cellular effector mechanisms, after the mixture of antibody and cells has been infused.
GVHD was well controlled in the majority of patients, irrespective of the antibody concentration or the use of post-transplant immunosuppression. The overall incidence of acute and chronic GVHD was similar to that seen when CAMPATH-1 antibodies were used in previous studies for T cell depletion of bone marrow transplants 3, 4, 10, 11 and is also similar to that seen using other effective methods for depleting donor T cells. However, there was a higher incidence of grade I acute GVHD and of mild/moderate chronic GVHD in patients who received CAMPATH-1H, despite the fact that the average antibody dose was slightly higher. The reason for this is not known, although it is notable that the starting concentration of T cells in the CAMPATH-1H group was significantly higher. Limited GVHD has not been a major clinical problem; in fact, there is some reason to believe that it may provide a desirable graft-versusleukemia effect.
The incidence of graft failure or graft rejection in this series of patients was low. Engraftment is probably facilitated by the larger number of stem cells available from peripheral blood compared with bone marrow. In addition, the surplus CAMPATH-1 antibody infused with the transplant probably contributes by depleting any residual host lymphocytes which have been spared by the conditioning regimen. In this regard, the present approach is superior to those methods which rely purely on ex vivo means, such as magnetic beads, for removing donor T cells. 20, 25 As with most clinical studies of stem cell transplantation, there are never sufficient patients to allow prospective randomized trials for comparing different treatments. Instead, we are obliged to rely on historical comparisons and a registry style of statistical analysis to elucidate significant trends. Only the most obvious conclusions can be drawn from the type of comparison presented in Table 6 , since we have to acknowledge that the groups of patients are not necessarily equivalent in terms of prognostic factors. However, each group involved consecutive patients treated in at least six different centers, so the data should be representative of typical clinical experience. The average number of CD34 + cells infused in this study was similar to that for unmanipulated PBSC and about twice that for CD34
+ selected PBSC where the recovery is typically about 50%. Clearly, T cell depletion results in a significant reduction in the risks of acute and chronic GVHD, and this is most striking in the CAMPATH groups because little or no posttransplant immunosuppression was used, whereas all of the patients in the CD34 + selected group also received posttransplant CyA. The risk of graft failure is lower for T celldepleted PBSC transplants compared with T cell-depleted bone marrow transplants, probably because of the larger dose of stem cells, which also results in significantly faster engraftment. However, the use of CAMPATH-1G or CAM-PATH-1H in PBSC transplants has not been associated with a reduction in transplant-related mortality. Whereas deaths from complications of GVHD are greatly reduced by T cell-depletion, it appears that there is still a risk from infectious complications.
Thus the two outstanding problems are leukemia relapse and immune reconstitution. An increased risk of relapse is likely for patients with CML who received T cell-depleted allogeneic transplants compared with recipients of T cellreplete transplant. 26 In future, this might be overcome by controlled infusion of donor leukocytes, but this needs to be done without risking severe GVHD. Any increase in relapse risk for patients with acute leukemia is modest, and probably compensated by the reduction in GVHD. 10, 27 In previous studies we observed that patients who received T cell-depleted bone marrow transplants were at risk from infections mainly during the first year post transplant. After that the 10 year actuarial risk of death from infection was only 3.5% (GH and CAMPATH users, unpublished work, 1998). Nevertheless, immune reconstitution after T celldepleted PBSC transplants is an issue of concern and needs to be studied in much more detail over a long term. Such a study has been carried out on 20 T cell-depleted bone marrow transplants by one of the present centers. 28 Immunophenotyping showed that CD8 + T cells and NK cells were within normal ranges from 8 weeks post transplant, whereas B cells recovered by about 24 weeks and total T cells reached the normal range by 1 year. However, CD4
+ T cells still remained at subnormal levels. A substantial proportion (14/20) patients developed serious infections at some stage post transplant, but this did not correlate with the absolute values of any of the lymphocyte subsets.
Another potential complication of T cell depletion is the risk of uncontrolled proliferation of Epstein-Barr virus Bone Marrow Transplantation (EBV) and consequent lymphoproliferative disease (BLPD), possibly leading to fatal lymphoma. There was one such case in this series of 187 patients. In a published study of 2582 bone marrow transplants T cell-depleted with CAMPATH-1 antibodies, the risk of BLPD was only 1.3%, hardly different from results for T cell-replete transplants, but in stark contrast to the high incidences reported following some other forms of T cell depletion. 29 The difference may be due to the fact that CAMPATH-1 antibodies target donor B cells equally as well as T cells thus reducing the virus load or the virus target or both.
Treatment with CAMPATH-1H is a simple and reliable method for prevention of GVHD and graft failure following allogeneic peripheral blood stem cell transplantation. The procedure results in a good yield of CD34 + cells and effective control of GVHD under a wide range of conditions. It may be suitable not only for allogeneic transplants but also for depletion of T cells in autologous transplant procedures for autoimmune diseases. During the period of this study there were very few PBSC transplants from volunteer unrelated donors. However, CAMPATH-1 antibodies have proved to be effective in controlling GVHD following unrelated donor marrow transplantation 4,30 so we hope that the present approach may also be useful if and when donations of blood stem cells from unrelated donors become more widely used. The important issue of immune reconstitution needs to be addressed and the possibility of using donor lymphocyte infusions should be considered especially if methods can be developed to manipulate them to selectively remove alloreactivity. 31 
